 Ahmet Aydin
Concepts (144)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Penile Neoplasms | 7 | 2025 | 45 | 3.760 |
Why?
| | Urinary Bladder Neoplasms | 7 | 2022 | 166 | 2.890 |
Why?
| | Carcinoma, Squamous Cell | 5 | 2021 | 331 | 1.840 |
Why?
| | Carcinoma, Transitional Cell | 3 | 2022 | 54 | 1.460 |
Why?
| | Prostatic Neoplasms | 3 | 2020 | 398 | 1.440 |
Why?
| | Kidney Neoplasms | 5 | 2021 | 181 | 1.430 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 3 | 2021 | 86 | 1.350 |
Why?
| | Carcinoma, Renal Cell | 4 | 2021 | 112 | 0.950 |
Why?
| | Immunotherapy | 6 | 2021 | 251 | 0.830 |
Why?
| | Pheochromocytoma | 1 | 2023 | 35 | 0.820 |
Why?
| | Adrenal Gland Neoplasms | 1 | 2023 | 49 | 0.810 |
Why?
| | Urothelium | 1 | 2021 | 19 | 0.690 |
Why?
| | BCG Vaccine | 2 | 2020 | 16 | 0.670 |
Why?
| | Neoadjuvant Therapy | 5 | 2022 | 124 | 0.660 |
Why?
| | Indocyanine Green | 1 | 2020 | 29 | 0.660 |
Why?
| | Cancer Vaccines | 1 | 2021 | 78 | 0.650 |
Why?
| | Ubiquitin Thiolesterase | 2 | 2021 | 17 | 0.650 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2021 | 140 | 0.640 |
Why?
| | Adjuvants, Immunologic | 1 | 2020 | 51 | 0.630 |
Why?
| | Male | 25 | 2025 | 26874 | 0.630 |
Why?
| | Anesthesia, Local | 1 | 2019 | 18 | 0.610 |
Why?
| | Tumor Suppressor Proteins | 2 | 2021 | 127 | 0.610 |
Why?
| | Edetic Acid | 1 | 2019 | 13 | 0.610 |
Why?
| | Immunotherapy, Adoptive | 1 | 2021 | 156 | 0.600 |
Why?
| | Patient Readmission | 1 | 2021 | 249 | 0.600 |
Why?
| | Testicular Neoplasms | 4 | 2021 | 46 | 0.600 |
Why?
| | Ureteral Neoplasms | 1 | 2019 | 11 | 0.600 |
Why?
| | Prostate-Specific Antigen | 1 | 2019 | 41 | 0.600 |
Why?
| | Papillomavirus Infections | 1 | 2021 | 170 | 0.590 |
Why?
| | Oligopeptides | 1 | 2019 | 94 | 0.570 |
Why?
| | Neoplasm Recurrence, Local | 4 | 2021 | 639 | 0.540 |
Why?
| | Humans | 31 | 2025 | 52441 | 0.540 |
Why?
| | Cystectomy | 3 | 2022 | 52 | 0.520 |
Why?
| | Arteriovenous Fistula | 1 | 2016 | 27 | 0.490 |
Why?
| | Neoplasms, Germ Cell and Embryonal | 3 | 2021 | 20 | 0.450 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 4 | 2022 | 1020 | 0.430 |
Why?
| | Middle Aged | 12 | 2025 | 13133 | 0.420 |
Why?
| | Retrospective Studies | 9 | 2022 | 6694 | 0.410 |
Why?
| | Aged | 11 | 2025 | 10242 | 0.400 |
Why?
| | Lymphatic Metastasis | 4 | 2021 | 210 | 0.400 |
Why?
| | Neoplasm Grading | 4 | 2020 | 127 | 0.380 |
Why?
| | Neoplasm Invasiveness | 3 | 2022 | 278 | 0.360 |
Why?
| | Tumor Microenvironment | 3 | 2021 | 257 | 0.330 |
Why?
| | Female | 14 | 2025 | 28277 | 0.320 |
Why?
| | Lymph Nodes | 2 | 2021 | 253 | 0.300 |
Why?
| | Antineoplastic Agents | 4 | 2025 | 1216 | 0.270 |
Why?
| | Treatment Outcome | 7 | 2022 | 5508 | 0.270 |
Why?
| | Prognosis | 3 | 2020 | 2100 | 0.240 |
Why?
| | Social Stigma | 1 | 2025 | 50 | 0.230 |
Why?
| | Adult | 9 | 2025 | 14205 | 0.220 |
Why?
| | Neoplasm Metastasis | 3 | 2021 | 235 | 0.220 |
Why?
| | Postoperative Complications | 3 | 2021 | 1065 | 0.220 |
Why?
| | Osteoporosis | 1 | 2025 | 157 | 0.210 |
Why?
| | Quality of Life | 2 | 2020 | 893 | 0.210 |
Why?
| | Early Detection of Cancer | 1 | 2025 | 185 | 0.210 |
Why?
| | Adrenalectomy | 1 | 2023 | 33 | 0.210 |
Why?
| | Adrenal Glands | 1 | 2023 | 38 | 0.210 |
Why?
| | Public Health | 1 | 2025 | 224 | 0.200 |
Why?
| | Neoplasm Staging | 3 | 2021 | 768 | 0.190 |
Why?
| | Deoxycytidine | 1 | 2022 | 24 | 0.190 |
Why?
| | Aged, 80 and over | 2 | 2021 | 3449 | 0.190 |
Why?
| | Retroperitoneal Space | 2 | 2021 | 25 | 0.190 |
Why?
| | Muscles | 1 | 2022 | 108 | 0.180 |
Why?
| | Cohort Studies | 3 | 2021 | 1576 | 0.180 |
Why?
| | Mycobacterium bovis | 1 | 2021 | 11 | 0.170 |
Why?
| | Antigens, Differentiation, Myelomonocytic | 1 | 2021 | 38 | 0.170 |
Why?
| | Aftercare | 1 | 2021 | 67 | 0.170 |
Why?
| | T-Lymphocytes | 2 | 2020 | 318 | 0.170 |
Why?
| | Lymph Node Excision | 2 | 2021 | 133 | 0.170 |
Why?
| | Teratoma | 1 | 2021 | 23 | 0.170 |
Why?
| | Interleukin-2 | 1 | 2021 | 69 | 0.170 |
Why?
| | Reference Standards | 1 | 2020 | 51 | 0.170 |
Why?
| | Tomography, Emission-Computed | 1 | 2020 | 53 | 0.170 |
Why?
| | Fluorouracil | 1 | 2020 | 56 | 0.170 |
Why?
| | Cisplatin | 1 | 2022 | 282 | 0.170 |
Why?
| | Lymphocyte Activation | 1 | 2021 | 161 | 0.170 |
Why?
| | Recurrence | 2 | 2019 | 680 | 0.160 |
Why?
| | Carcinoma in Situ | 1 | 2020 | 72 | 0.160 |
Why?
| | Antigens, CD | 1 | 2021 | 213 | 0.160 |
Why?
| | Sentinel Lymph Node Biopsy | 1 | 2020 | 119 | 0.160 |
Why?
| | Survival Rate | 2 | 2019 | 944 | 0.150 |
Why?
| | Gallium Isotopes | 1 | 2019 | 2 | 0.150 |
Why?
| | Gallium Radioisotopes | 1 | 2019 | 9 | 0.150 |
Why?
| | Patient Discharge | 1 | 2021 | 320 | 0.150 |
Why?
| | Kidney Pelvis | 1 | 2019 | 16 | 0.150 |
Why?
| | Disease-Free Survival | 1 | 2020 | 461 | 0.150 |
Why?
| | Prospective Studies | 2 | 2025 | 2433 | 0.150 |
Why?
| | Genomics | 1 | 2020 | 266 | 0.150 |
Why?
| | Feasibility Studies | 1 | 2020 | 404 | 0.150 |
Why?
| | Papillomavirus Vaccines | 1 | 2019 | 69 | 0.140 |
Why?
| | Urologic Neoplasms | 1 | 2018 | 12 | 0.140 |
Why?
| | Ureteral Obstruction | 1 | 2019 | 62 | 0.140 |
Why?
| | Carcinoma, Papillary | 1 | 2018 | 49 | 0.140 |
Why?
| | Genetic Predisposition to Disease | 1 | 2020 | 525 | 0.130 |
Why?
| | Cells, Cultured | 1 | 2021 | 1583 | 0.130 |
Why?
| | Biopsy | 1 | 2019 | 594 | 0.130 |
Why?
| | Cell Proliferation | 1 | 2021 | 1013 | 0.130 |
Why?
| | Renal Artery | 1 | 2016 | 32 | 0.120 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2020 | 853 | 0.120 |
Why?
| | Nephrectomy | 1 | 2016 | 81 | 0.120 |
Why?
| | Time Factors | 2 | 2020 | 2987 | 0.120 |
Why?
| | Neoplasms | 1 | 2025 | 1314 | 0.120 |
Why?
| | Risk Factors | 2 | 2025 | 3971 | 0.120 |
Why?
| | Urinary Tract Infections | 1 | 2015 | 56 | 0.110 |
Why?
| | Laparoscopy | 1 | 2016 | 180 | 0.110 |
Why?
| | Kidney Failure, Chronic | 1 | 2015 | 205 | 0.100 |
Why?
| | Kidney Transplantation | 1 | 2015 | 199 | 0.100 |
Why?
| | Chemotherapy, Adjuvant | 2 | 2020 | 122 | 0.080 |
Why?
| | Kaplan-Meier Estimate | 2 | 2021 | 485 | 0.080 |
Why?
| | Follow-Up Studies | 3 | 2020 | 2294 | 0.070 |
Why?
| | Survival Analysis | 2 | 2021 | 656 | 0.070 |
Why?
| | Absorptiometry, Photon | 1 | 2025 | 161 | 0.060 |
Why?
| | Bone Diseases, Metabolic | 1 | 2025 | 80 | 0.060 |
Why?
| | Propensity Score | 1 | 2025 | 160 | 0.060 |
Why?
| | Lumbar Vertebrae | 1 | 2025 | 99 | 0.060 |
Why?
| | Bone Density | 1 | 2025 | 396 | 0.050 |
Why?
| | Case-Control Studies | 1 | 2025 | 1202 | 0.050 |
Why?
| | T-Lymphocyte Subsets | 1 | 2021 | 40 | 0.040 |
Why?
| | Immune System | 1 | 2021 | 42 | 0.040 |
Why?
| | Administration, Topical | 1 | 2020 | 62 | 0.040 |
Why?
| | Forkhead Transcription Factors | 1 | 2021 | 120 | 0.040 |
Why?
| | Cross-Sectional Studies | 1 | 2025 | 1677 | 0.040 |
Why?
| | Urinary Bladder | 1 | 2020 | 101 | 0.040 |
Why?
| | Patient Selection | 1 | 2020 | 269 | 0.040 |
Why?
| | Treatment Failure | 1 | 2019 | 117 | 0.040 |
Why?
| | Macrophages | 1 | 2021 | 357 | 0.040 |
Why?
| | Socioeconomic Factors | 1 | 2020 | 609 | 0.030 |
Why?
| | Health Facilities | 1 | 2017 | 39 | 0.030 |
Why?
| | Oncolytic Virotherapy | 1 | 2017 | 19 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2018 | 641 | 0.030 |
Why?
| | Adolescent | 2 | 2019 | 6713 | 0.030 |
Why?
| | Turkey | 1 | 2015 | 17 | 0.030 |
Why?
| | Mutation | 1 | 2021 | 1331 | 0.030 |
Why?
| | Clinical Trials as Topic | 1 | 2017 | 461 | 0.030 |
Why?
| | Child | 2 | 2019 | 7194 | 0.030 |
Why?
| | Graft Survival | 1 | 2015 | 157 | 0.030 |
Why?
| | Cytokines | 1 | 2017 | 622 | 0.030 |
Why?
| | Registries | 1 | 2017 | 638 | 0.030 |
Why?
| | Antibodies, Monoclonal | 1 | 2017 | 475 | 0.030 |
Why?
| | Mice | 1 | 2020 | 5899 | 0.020 |
Why?
| | Child, Preschool | 1 | 2019 | 4046 | 0.020 |
Why?
| | Young Adult | 1 | 2018 | 4346 | 0.020 |
Why?
| | United States | 1 | 2017 | 5215 | 0.020 |
Why?
| | Animals | 1 | 2020 | 13485 | 0.010 |
Why?
|
|
Aydin's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|